Articles On Kazia Therapeutics (ASX:KZA)

Bell Potter has maintained its Speculative Buy rating and valuation of A$2.76 per share for Kazia (current share price: A$1.16).

The company's clinical trial of multiple therapies is set to open in the US in the first half of 2021 before its expansion to other countries later in 2021.

Source: Shutterstock Summary Kazia Therapeutics announced the execution of a Letter of Intent with Pacific Pediatric Neuro-Oncology Consortium. As part of the collaboration, a clinical trial would be conducted for multiple therapies,...

The clinical trial will initially open in the US in the first half of 2021, with expansion to other countries in 2021, with talks ongoing on the potential inclusion of Australian sites

The trial returned positive results and the company intends to shift towards partnering activity to continue the drug's development.

09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Edison Investment Research has increased its valuation on Kazia to A$2.04 per share from A$1.54 per share.

The Kazia Therapeutics Ltd (ASX: KZA) share price is one of the best performers on the ASX this past month, almost doubling in value before retreating today by 12% to $1.53. Overall, the drugmaker’s share price has gained over 82% during t...

The Kazia Therapeutics Ltd [ASX:KZA] share price is following an upward trend. While this small-cap biotech may not be trying to treat COVID, they are trying to treat an equally sinister disease: glioblastoma. The post Kazia Therapeutics Sh...

ShareCafeWhy Kazia Therapeutics is Australia’s biotech shining star Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corpora...

Summary Kazia Therapeutics has announced that it will present the summary of paxalisib’s new Phase II study data at the SNO Annual Meeting to be held during 19-21 November. The new interim data of paxalisib in glioblastoma is consistent...

The paxalisib Phase II study remains ongoing, with final data expected in the first half of 2021.

During the September quarter the company’s Paxalisib drug was granted special designations by US FDA, Rare Pediatric Disease Designation in DIPG, Orphan Designation in glioma, and Fast Track Designation in glioblastoma.

The company’s investigational new drug paxalisib is being developed to treat glioblastoma (GBM), an aggressive type of brain cancer, and other cancers.

Kazia is laying the groundwork to develop its investigational new drug paxalisib for glioblastoma and other types of cancers.

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced it has executed a definitive agreement with the Global Coalition for Adaptive Research to commence its participation in the GBM AGILE pivot...

GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international platform study that has been established specifically to facilitate the approval of new medicines for glioblastoma.

Proceeds form the entitlement offer will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

By Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt this year is the power of small cap companies to drive your portfolio’s value higher. This revelation makes me even more committed to the ide...

ShareCafeAntisense Eyes A ‘Golden Ticket’ In The US – And Early European Approval For Its Rare Childhood Disease Therapy Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its n...

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced the successful completion of the institutional component of its capital raise.

A number of companies got a nice share price boost after positive announcements this week Starpharma and Kazia Therapeutics launched ... Read More The post ScoPo’s Health Powerplays: Biotechs hitting it out of the park appeared first on Sto...

The funding will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

The financing will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

The Dana-Farber Cancer institute will initiate an open-label phase II clinical trial of paxalisib in primary central nervous system lymphoma, which is expected to recruit up to 25 patients, and take up to two years to complete.

Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.

ShareCafeKazia Therapeutic’s New Collaboration Gives Their Cancer Drug New Potential For Treatment Of Lymphoma   Kazia Therapeutics (ASX: KZA) is an Australian oncology company developing high-impact drugs for cancer. paxalisib, which is b...

The institute will initiate an open-label phase II clinical trial of paxalisib in primary central nervous system lymphoma, which is expected to recruit up to 25 patients, and take up to two years to complete.

Kazia said the collaboration will investigate the use of its investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system lymphoma.

Edison Investment Research has reinitiated coverage on Kazia with a valuation of A$145 million or A$1.54 per share.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

The company’s paxalisib treatment for malignant glioma has been recently granted Orphan Drug Designation by the US FDA.

ShareCafeWith A ‘Ticket To Ride’, Kazia Wows Investors With Its Rare-Cancer Story   As the political schisms in the US widen there’s one element that does not discriminate between the major parties: the most common form of brain cancer. Kn...

This status for potential treatments for rare diseases provides a period of 7.5 years data exclusivity (for a paediatric disease), which allows developers to extend the effective life of a commercial product.

A quick wrap of the ASX’s key winners and losers on Thursday, August 20. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 553 stocks rose, 765 declined and...

Kazia Therapeutics Ltd (ASX: KZA) share price has skyrocketed 34% today after announcing the US Food and Drug Administration (FDA) had granted fast track designation (FTD) for Kazia’s drug, paxalisib. Paxalisib is used for the treatment of...

Just under two weeks ago, Kazia Therapeutics Ltd [ASX:KZA] was making headlines. The company had received ‘the nod’ from the US Food and Drug Administration (FDA) it sorely needed... The post Kazia Therapeutics Share Price Storms Higher on...

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has been granted Fast Track Designation by the US Food & Drug Administration for its lead drug paxalisib (formerly GDC-0084) for the treatment of glioblasto...

Cancer-fighting biotech Kazia Therapeutics (ASX:KZA) has received another approval from US health authorities, as it continues with phase II clinical trials for its brain cancer treatment. The company announced its paxalisib treatment has b...

Fast Track Designation (FTD) is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Kazia Therapeutics (ASX:KZA), an Australian oncology-focused biotechnology company, has announced that the US FDA has granted Fast Track Designation (FTD) to its paxalisib (formerly GDC-0084) for the treatment of glioblastoma.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Summary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA. With the RPDD grant, Kazia Therapeutics may now be eligible to receive a rare pediatric disease priority review voucher if paxalisib gets ap...

The share price of oncology-focused biotech firm, KAZIA Therapeutics Ltd [ASX:KZA], soared this morning on the receipt of FDA designation for its brain cancer treatment. At time of writing the KZA share price is up 26 cents or 46.43%, tradi...

A quick wrap of the ASX’s key winners and losers on Friday, August 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 679 stocks rose, 666 dec...

The Kazia Therapeutics Ltd (ASX: KZA) share price has today smashed its 52-week high on news that the United States Food and Drug Administration (FDA) has awarded a grant for Kazia’s flagship drug. The oncology-focused biotech company has...

The US FDA has awarded RPDD to paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and highly aggressive childhood brain cancer.